CRISPR Therapeutics is advancing CTX310, a one-time intravenous CRISPR-Cas9 therapy designed to disable the ANGPTL3 gene, which regulates blood-fat levels.
In a 15-person Phase 1 study, the highest tested dose—0.8 mg/kg—produced substantial reductions in LDL (“bad”) cholesterol and triglycerides. Reported averages were roughly 49% lower LDL and 55% lower triglycerides after about 60 days.
Follow-up data indicated that the effect persisted for one year:
LDL fell by about 53% and triglycerides by about 48% among the highest-dose participants. ANGPTL3 levels declined by roughly 79%.
The treatment was generally well tolerated, with no treatment-related serious adverse events reported. Some infusion-related reactions, including fever, nausea and back pain, occurred at higher doses.
Because the trial was small and early-stage, the results do not establish long-term safety or cardiovascular benefit. Gene-editing patients require extended monitoring, reportedly up to 15 years.
CRISPR Therapeutics is pursuing a Phase 1b study, prioritizing severe hypertriglyceridemia and mixed dyslipidemia, using a dose equivalent to the 0.8 mg/kg level.
Sources:
Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing ...
An Experimental One-Time Treatment for High Cholesterol Shows ...
CRISPR Therapeutics Announces Positive Phase 1…
Crispr Therapeut (CRSP) Stock News & Updates
CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study
Gene editing may lower bad cholesterol for life
CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for ...
CRISPR vs cholesterol: can gene editing prevent heart disease?
Gene Editing for the Treatment of Hypercholesterolemia - PMC
First-in-human gene editing for lipid lowering: the initial results - PMC
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ...
Gene Editing Therapies Targeting Lipid Metabolism for ... - PMC